CY1124130T1 - Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων - Google Patents

Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων

Info

Publication number
CY1124130T1
CY1124130T1 CY20211100266T CY211100266T CY1124130T1 CY 1124130 T1 CY1124130 T1 CY 1124130T1 CY 20211100266 T CY20211100266 T CY 20211100266T CY 211100266 T CY211100266 T CY 211100266T CY 1124130 T1 CY1124130 T1 CY 1124130T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
vardoxolone
polymorphines
difluoropropionamide
methylate
Prior art date
Application number
CY20211100266T
Other languages
English (en)
Inventor
Andrea Decker
Eric Anderson
Xiaofeng Liu
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of CY1124130T1 publication Critical patent/CY1124130T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται γενικά με την ένωση: Ν-((4aS,6aR,6bS,8aR,12aS, 14aR, 14bS)-11-κυαν-2,2,6a,6b,9,9, 12a-επταμεθυλο-10, 14-διοξο-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9, 10, 12a, 14, 14a, 14b-οκταδεκαϋδροπισεν-4a-υλο)-2,2-διφθοροπροπαναμίδιο και πολυμορφικές μορφές και φαρμακευτικές σύνθεσης αυτής για χρήση στη θεραπευτική αντιμετώπιση του καρκίνου σε συνδυασμό με ανοσοθεραπεία, για χρήση στη θεραπευτική αντιμετώπιση παθήσεων που συνδέονται με οξειδωτικό στρες το οποίο προκαλείται από μιτοχονδριακή δυσλειτουργία και για χρήση στη θεραπευτική αντιμετώπιση διαταραχών κρίσεων.
CY20211100266T 2012-04-27 2021-03-26 Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων CY1124130T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261687669P 2012-04-27 2012-04-27
US201361775288P 2013-03-08 2013-03-08
US201361780444P 2013-03-13 2013-03-13
PCT/US2013/038064 WO2013163344A1 (en) 2012-04-27 2013-04-24 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
EP13720708.0A EP2841445B1 (en) 2012-04-27 2013-04-24 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1124130T1 true CY1124130T1 (el) 2022-05-27

Family

ID=49483867

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100959T CY1119333T1 (el) 2012-04-27 2017-09-12 Παραγωγα 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, πολυμορφικες μορφες και μεθοδοι χρησης αυτων
CY20211100266T CY1124130T1 (el) 2012-04-27 2021-03-26 Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100959T CY1119333T1 (el) 2012-04-27 2017-09-12 Παραγωγα 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, πολυμορφικες μορφες και μεθοδοι χρησης αυτων

Country Status (39)

Country Link
US (4) US8993640B2 (el)
EP (2) EP3444261B1 (el)
JP (2) JP6410710B2 (el)
KR (1) KR102101774B1 (el)
CN (1) CN104395332B (el)
AR (1) AR092823A1 (el)
AU (1) AU2013251602B2 (el)
BR (1) BR112014026640B1 (el)
CA (1) CA2869783C (el)
CL (1) CL2014002886A1 (el)
CO (1) CO7170182A2 (el)
CY (2) CY1119333T1 (el)
DK (2) DK3444261T3 (el)
DO (1) DOP2014000236A (el)
EA (1) EA030468B1 (el)
ES (2) ES2861393T3 (el)
FI (1) FIC20240012I1 (el)
FR (1) FR24C1015I1 (el)
HK (2) HK1207085A1 (el)
HR (1) HRP20171275T1 (el)
HU (3) HUE035673T2 (el)
IL (1) IL235275B (el)
LT (2) LT3444261T (el)
ME (1) ME02926B (el)
MX (1) MX357060B (el)
MY (1) MY172750A (el)
NL (1) NL301276I2 (el)
NZ (1) NZ630222A (el)
PE (1) PE20150160A1 (el)
PL (2) PL3444261T3 (el)
PT (2) PT3444261T (el)
RS (2) RS61544B1 (el)
SG (1) SG11201406868XA (el)
SI (2) SI2841445T1 (el)
TW (2) TWI623548B (el)
UA (1) UA116209C2 (el)
UY (1) UY34764A (el)
WO (1) WO2013163344A1 (el)
ZA (1) ZA201407326B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711834C (en) 2008-01-11 2017-03-14 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
WO2012083306A2 (en) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
PL3444261T3 (pl) 2012-04-27 2021-07-19 Reata Pharmaceuticals, Inc. Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
TWI649330B (zh) * 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2018089539A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
EP3803409A1 (en) * 2018-05-24 2021-04-14 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
AU2019286531B2 (en) 2018-06-15 2024-07-18 Reata Pharmaceuticals, Inc. Pyrazole and imidazole compounds for inhibition of IL-17 and rorgamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
DK3833662T3 (da) 2018-08-20 2024-02-26 Janssen Pharmaceutica Nv Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
US20220133748A1 (en) * 2019-02-15 2022-05-05 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
BR112022014660A2 (pt) 2020-01-24 2022-09-13 Tvardi Therapeutics Inc Compostos terapêuticos, formulações e usos dos mesmos
US20240293351A1 (en) 2020-12-11 2024-09-05 Reata Pharmaceuticals Holdings, LLC Methods of administering synthetic triterpenoids
JP2024504637A (ja) * 2021-01-18 2024-02-01 リアタ ファーマシューティカルズ インコーポレイテッド 合成ウルソール酸誘導体及びその使用方法
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) * 2021-06-23 2022-07-01 华中农业大学 一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
WO2023244946A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. Prodrugs of stat3 inhibitors
EP4349847A1 (en) 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5555153Y2 (el) 1975-03-19 1980-12-20
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
NZ540001A (en) 1999-05-14 2007-06-29 Nereus Pharmaceuticals Inc Novel interleukin-1 and tumor necrosis factor-alpha modulators syntheses of said modulators and methods of using said modulators
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
WO2002026761A1 (en) 2000-09-29 2002-04-04 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
WO2002047611A2 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CN1636058B (zh) 2001-05-14 2011-06-08 龚大为 新型丙氨酸转氨酶及其应用方法
WO2003059339A1 (en) 2002-01-15 2003-07-24 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1465914B1 (en) 2002-01-18 2008-12-17 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
EP1507541A4 (en) 2002-05-13 2009-06-03 Dartmouth College HEMMER AND APPLICATION METHOD THEREFOR
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
WO2006029221A2 (en) 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007112043A2 (en) 2006-03-23 2007-10-04 Advanced Life Sciences Inc. Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin
US20070249561A1 (en) 2006-04-25 2007-10-25 Taylor Bradley K Pharmacological method for treatment of neuropathic pain
CA2653726C (en) 2006-06-27 2015-05-12 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
US8299046B2 (en) 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
WO2012106190A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
WO2008111497A1 (ja) 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US20090048205A1 (en) 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
CA2711834C (en) 2008-01-11 2017-03-14 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
NZ588708A (en) 2008-04-18 2012-09-28 Reata Pharmaceuticals Inc 2-cyano steroid derivatives including an anti-inflammatory pharmacore
US8314137B2 (en) 2008-07-22 2012-11-20 Trustess Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CA2744388A1 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
WO2010093944A2 (en) 2009-02-13 2010-08-19 Reata Pharmaceuticals, Inc. Delayed release, oral dosage compositions that contain amorphous cddo-me
CA2760687A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
MX357596B (es) 2010-04-12 2018-07-16 Reata Pharmaceuticals Inc Método para tratar obesidad utilizando moduladores de inflamación con antioxidantes.
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
WO2012083306A2 (en) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
CN102153613B (zh) 2011-02-28 2013-08-14 贵州省中国科学院天然产物化学重点实验室 夏枯草酸的制备方法和应用
UY33946A (es) 2011-03-11 2012-08-31 Reata Pharmaceuticals Inc Derivados de c4-monometil triterpenoides y sus métodos de uso
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
PL3444261T3 (pl) 2012-04-27 2021-07-19 Reata Pharmaceuticals, Inc. Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, ich kompozycje farmaceutyczne i formy polimorficzne do zastosowania w leczeniu określonych stanów
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru) 2012-07-13 2013-07-20 Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
MX2015003021A (es) 2012-09-10 2015-11-09 Abbvie Inc Derivados de acido glicirretinico y metodos de uso de los mismos.
EP2892911B1 (en) 2012-09-10 2017-08-30 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
AU2012324029B2 (en) 2012-09-28 2015-05-14 Applied Pharmaceutical Science, Inc. Polymorphs of CDDO ethyl ester and uses thereof
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
EP3035937A1 (en) 2013-08-23 2016-06-29 Reata Pharmaceuticals, Inc. Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX2016009589A (es) 2014-01-24 2016-10-28 Abbvie Inc Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes.
CN107428698B (zh) 2015-02-12 2021-10-26 里亚塔医药公司 作为抗氧化炎症调节剂的咪唑基三环烯酮
CA2998681C (en) 2015-09-23 2024-02-06 Reata Pharmaceuticals, Inc. C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2018089539A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物

Also Published As

Publication number Publication date
US20150259377A1 (en) 2015-09-17
RS61544B1 (sr) 2021-04-29
RS56154B1 (sr) 2017-11-30
SG11201406868XA (en) 2014-11-27
TWI623548B (zh) 2018-05-11
EA030468B1 (ru) 2018-08-31
CA2869783A1 (en) 2013-10-31
LT3444261T (lt) 2021-05-10
SI3444261T1 (sl) 2021-04-30
US20130324599A1 (en) 2013-12-05
MX2014013076A (es) 2015-05-11
FR24C1015I1 (fr) 2024-06-28
CN104395332A (zh) 2015-03-04
BR112014026640A2 (pt) 2017-07-18
EP3444261A1 (en) 2019-02-20
AU2013251602B2 (en) 2017-09-28
US20210355156A1 (en) 2021-11-18
US12065464B2 (en) 2024-08-20
AR092823A1 (es) 2015-05-06
PT3444261T (pt) 2021-03-12
EP2841445B1 (en) 2017-06-14
HUS2400010I1 (hu) 2024-05-28
ME02926B (me) 2018-04-20
PE20150160A1 (es) 2015-02-19
CN104395332B (zh) 2017-01-18
US8993640B2 (en) 2015-03-31
DOP2014000236A (es) 2015-04-30
CY1119333T1 (el) 2018-02-14
EP2841445A1 (en) 2015-03-04
ES2861393T3 (es) 2021-10-06
KR20150003875A (ko) 2015-01-09
BR112014026640B1 (pt) 2021-05-18
EP3444261B1 (en) 2021-01-13
FIC20240012I1 (fi) 2024-04-18
JP2015521166A (ja) 2015-07-27
NL301276I2 (nl) 2024-06-24
TW201726701A (zh) 2017-08-01
US20180009839A1 (en) 2018-01-11
HRP20171275T1 (hr) 2017-10-20
US11078230B2 (en) 2021-08-03
PT2841445T (pt) 2017-09-01
HUE053113T2 (hu) 2021-06-28
NZ630222A (en) 2016-06-24
ES2634315T3 (es) 2017-09-27
PL3444261T3 (pl) 2021-07-19
PL2841445T3 (pl) 2017-10-31
JP6410710B2 (ja) 2018-10-24
IL235275B (en) 2018-03-29
MX357060B (es) 2018-06-25
UA116209C2 (uk) 2018-02-26
HUE035673T2 (en) 2018-05-28
MY172750A (en) 2019-12-11
CL2014002886A1 (es) 2015-02-06
US9701709B2 (en) 2017-07-11
ZA201407326B (en) 2016-10-26
JP6637136B2 (ja) 2020-01-29
CA2869783C (en) 2022-06-21
DK3444261T3 (da) 2021-03-08
TW201348245A (zh) 2013-12-01
KR102101774B1 (ko) 2020-04-20
LT2841445T (lt) 2017-09-11
UY34764A (es) 2013-11-29
SI2841445T1 (sl) 2017-12-29
HK1207085A1 (en) 2016-01-22
CO7170182A2 (es) 2015-01-28
HK1207086A1 (en) 2016-01-22
EA201491972A1 (ru) 2015-02-27
WO2013163344A1 (en) 2013-10-31
DK2841445T3 (en) 2017-09-11
AU2013251602A1 (en) 2014-10-23
JP2019011349A (ja) 2019-01-24

Similar Documents

Publication Publication Date Title
CY1124130T1 (el) Παραγωγο 2.2-διφθοροπροπιοναμιδιου απο μεθυλικη βαρδοξολονη, φαρμακευτικες συνθεσεις και πολυμορφικες μορφες τους για χρηση στη θεραπευτικη αντιμετωπιση συγκεκριμενων παθησεων
CY1120570T1 (el) Παραγωγα 2,2-διφθοροπροπιοναμιδης της μεθυλικης βαρδοξολονης, πολυμορφα και μεθοδοι χρησης αυτων
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
BR112014020826A2 (pt) moduladores e métodos de uso
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
GT201400085A (es) Profármaco de adrenomedulina basado en polietilenglicol y su uso
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
UY35746A (es) Derivados de fenilalanina sustituidos
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
UY36938A (es) Nuevos compuestos macrocíclicos modificados
CY1123044T1 (el) Νεες ενωσεις
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
UY35745A (es) Derivados sustituidos de fenilalanina
AR092247A1 (es) INHIBIDORES DE LA b-SECRETASA
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
BR112013029416A2 (pt) derivados de indol substituídos para o tratamento de distúrbios imunológicos
CU20180044A7 (es) Derivados novedosos de diamino piridina
CL2017002605A1 (es) Derivados de indol
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
EA201690236A1 (ru) Производные индол-3-карбинола